局部进展期直肠癌新辅助放化疗后转移淋巴结消退分级的预后价值
该研究回顾421例接受新辅助长程放化疗的直肠癌患者,按淋巴结消退分级(0-5级)评估预后。ypN0中淋巴结消退1级者5年无复发生存率和局部复发率与0级相似;ypN+者无论分级预后均差。完全淋巴结消退是强预后因素。
要点
- 淋巴结消退1级(完全纤维化)者预后与无转移淋巴结者相似
- ypN+患者即使淋巴结消退分级不同,预后均较差
- 强化全身化疗与更多淋巴结消退1级独立相关
核心结论
- 放化疗后完全淋巴结消退是直肠癌的强预后因素。
研究设计与样本
- 回顾性 review 421例接受新辅助长程放化疗的直肠癌患者。
- 淋巴结消退分级分为0级(正常淋巴结)、1级(100%纤维化)、2级(<25%癌细胞)、3级(25%-50%癌细胞)、4级(50%-75%癌细胞)、5级(>75%癌细胞)。
主要发现
- 301例ypN0患者中27例为淋巴结消退1级。
- 淋巴结消退1级患者5年无复发生存率96.3%、局部复发率0%,0级患者分别为88.1%和2.7%。
- 120例ypN+(淋巴结消退2-5级)患者5年无复发生存率38.1%-61.1%,局部复发率8.4%-14.0%。
- 多因素分析中,强化全身化疗与淋巴结消退1级独立相关(P < .001;OR=6.06;95%CI 2.33-16.20)。
- 多因素分析中,ypT3-4(HR=7.82;95%CI 2.80-27.32;P < .001)、淋巴结消退1级(HR=0.048;95%CI 0.002-0.27;P < .001)、检出淋巴结<12枚(HR=5.48;95%CI 1.48-16.38;P = .014)和无围手术期化疗(HR=3.01;95%CI 1.53-5.68;P = .002)是无复发生存独立预测因素。
临床怎么用
- 病理评估应关注淋巴结消退分级,完全淋巴结消退提示预后良好。
- ypN+患者即使淋巴结消退分级较低,仍需警惕复发风险。
- 强化全身化疗可能增加淋巴结完全消退机会。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognostic value of classifying the degree of metastatic lymph node regression grade after neoadjuvant chemoradiotherapy remains unclear. The aim was to assess the prognostic value of lymph node regression grade in patients with rectal cancer treated with chemoradiotherapy. METHODS: We reviewed a total of 421 patients with rectal cancer who underwent neoadjuvant long-course chemoradiotherapy. All lymph nodes were examined retrospectively for evidence of response to chemoradiotherapy, and lymph node regression grade was scored as lymph node regression grade 0 (normal lymph node), lymph node regression grade 1 (100% fibrosis), lymph node regression grade 2 (< 25% cancer cells), lymph node regression grade 3 (25%-50% cancer cells), lymph node regression grade 4 (50%-75% cancer cells), and lymph node regression grade 5 (> 75% cancer cells). The prognostic importance of lymph node regression grade was evaluated. RESULTS: Among 301 ypN0 patients, 27 patients were scored as lymph node regression grade 1. The 5-year recurrence-free survival and local recurrence rates in lymph node regression grade 1 patients were similar to those in lymph node regression grade 0 patients (96.3% versus 88.1% in recurrence-free survival and 0% versus 2.7% in local recurrence); however, among 120 ypN+ (lymph node regression grade 2-5) patients, the 5-year recurrence-free survival and local recurrence rates were poor regardless of the lymph node regression grade score (38.1%-61.1% in recurrence-free survival and 8.4%-14.0% in local recurrence). In the multivariate analysis, an intensified regimen using systemic chemotherapy was independently associated with more lymph node regression grade 1 (P < .001; odds ratio, 6.06; 95% confidence interval, 2.33-16.20) among patients with lymph node regressions grade 1 through 5. Furthermore, in the multivariate analysis, ypT3-4 (hazard ratio, 7.82; 95% confidence interval, 2.80-27.32; P < .001), lymph node regression grade 1 (hazard ratio, 0.048; 95% confidence interval, 0.002-0.27; P < .001), the number of retrieved lymph nodes < 12 (hazard ratio, 5.48; 95% confidence interval, 1.48-16.38; P = .014), and no perioperative chemotherapy (hazard ratio, 3.01; 95% confidence interval, 1.53-5.68; P = .002) were independent predictors of recurrence-free survival. CONCLUSION: Complete lymph node regression after chemoradiotherapy is a strong prognostic factor in rectal cancer.
引用
- Tominaga T, Akiyoshi T, Yamamoto N, et al. Prognostic value of metastatic lymph node regression grade after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Surgery. 2019. PMID: 31345564. doi:10.1016/j.surg.2019.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。